Cytokinetics, Incorporated
CYTK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.56 | -0.59 | -0.19 | -0.39 |
| FCF Yield | -7.59% | -5.16% | -7.55% | -5.46% |
| EV / EBITDA | -12.08 | -19.05 | -14.57 | -20.76 |
| Quality | ||||
| ROIC | -42.81% | -66.20% | -34.35% | -23.31% |
| Gross Margin | -1,737.22% | -4,284.10% | -154.59% | -127.09% |
| Cash Conversion Ratio | 0.67 | 0.79 | 0.77 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -41.98% | -52.54% | 19.21% | 37.88% |
| Free Cash Flow Growth | 3.84% | -33.75% | -62.41% | -8,975.11% |
| Safety | ||||
| Net Debt / EBITDA | -1.41 | -1.41 | -2.08 | -0.89 |
| Interest Coverage | -6.20 | -8.60 | -6.34 | -6.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -1,638.18 | 0.00 |
| Cash Conversion Cycle | 307.06 | 38.41 | -38.47 | 220.43 |